oxy update out - stay tuned, page-88

We know we have the cash put aside to complete trials of Oxycodone. And we also know the big cost of trails comes at phase 3 with the increased size of the trail. We also know that the company has regularly said that they do not envisage going through FDA approval without a Big Pharma partner.

Assuming we start Phase 1 oxymorphone around the same time as multidosing in oxycodone and then multidosing on oxycodone at the same time as phase 3 on oxycontin then why is it a stretch to think that Big Pharma will snatch up the "pain portfolio" before the company has had to incurr the cost of a phase 3 on oxymorphone as it won't be a stretch for them to see that after one opioid has past through all trials with flying colours and the second compound has the same/similar profile after multi dosing that phase 3 is a given and worth putting their cash on the line to buy oxymorphone ahead of trial completion.

In fact ultimately once we get one drug (oxycodone) over the line Big Pharma (and the market) should begin to understand what we have all known for some time - that once proof of absorbtion is proved in phase 1 then the remainder of trials for this new delivery system (for what is already an approved active) is just a matter of process rather than significant risk.